行情

XOMA

XOMA

标记临床研究
NASDAQ

实时行情|Nasdaq Last Sale

24.24
-0.88
-3.50%
已收盘, 16:00 11/21 EST
开盘
25.35
昨收
25.12
最高
25.56
最低
24.04
成交量
4.39万
成交额
--
52周最高
26.90
52周最低
11.02
市值
2.12亿
市盈率(TTM)
-207.8902
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

XOMA 新闻

  • The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
  • Benzinga.2天前
  • Xoma readies rights offering
  • Seeking Alpha - Article.2天前
  • XOMA Reports $22M Rights Offering
  • Benzinga.2天前
  • XOMA Announces Proposed Rights Offering
  • GlobeNewswire.2天前

更多

所属板块

生物技术和医学研究
-0.12%
制药与医学研究
+0.43%

热门股票

名称
价格
涨跌幅

XOMA 简况

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
展开

Webull提供XOMA Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。